Search

Displaying results 891 - 900 of 4626 in total
  1. Drug

    Enasidenib

    go.drugbank.com/drugs/DB13874
    ApprovedInvestigational

    First developed by Agios Pharmaceuticals and licensed to Celgene, enasidenib was approved by U.S. Food and Drug Administration on August 1, 2017. … Patients eligible for this treatment are selected by testing the presence of IDH2 mutations in the blood or bone marrow.

  2. Drug

    Rezafungin

    go.drugbank.com/drugs/DB16310
    ApprovedInvestigational

    high plasma exposure. … It can only be administered intravenously but does not reach therapeutic concentrations in the central nervous system, eye and urine.

  3. Drug

    Doxycycline

    go.drugbank.com/drugs/DB00254
    ApprovedInvestigationalVet approved

    Doxycycline is a broad-spectrum antibiotic synthetically derived from oxytetracycline. It is a second-generation tetracycline that was first discovered in 1967. Second-generation tetracyclines exhibit lesser toxicity than first-generatio...

  4. Drug

    Erythropoietin

    go.drugbank.com/drugs/DB00016
    ApprovedInvestigational

    recombinant DNA technology and is used for the treatment of patients with anemia associated with various clinical conditions, such as chronic renal failure, antiviral drug therapy, chemotherapy, or a high … Epoetin alfa (Epoge) was developed by Amgen Inc. in 1983 as the first rhEPO commercialized in the United States, followed by other alfa and beta formulations.

  5. Drug

    Influenza A Virus A/Sydney/5/2021 SAN-013 (H1N1) antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB17751
    ApprovedWithdrawn

    These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes

    Mixtures: FLUZONE High-Dose Quadrivalent Southern Hemisphere
  6. Drug

    Cladribine

    go.drugbank.com/drugs/DB00242
    ApprovedInvestigational

    Cladribine is a purine analogue or a chlorinated derivative of adenine that causes apoptosis of B and T lymphocytes. Cladribine was first approved in the United States in 1993 initially as a treatment for a number of hematological malign...

  7. Drug

    Carbocisteine

    go.drugbank.com/drugs/DB04339
    ApprovedInvestigational

    [A230993] Carbocisteine is currently not FDA or Health Canada approved, but is approved for use in Asia, Europe, and South America. … Carbocisteine is a mucolytic drug that alleviates respiratory symptoms and infections by reducing the viscosity of mucus, allowing it to be expelled.

  8. Drug

    Linezolid

    go.drugbank.com/drugs/DB00601
    ApprovedInvestigational

    Linezolid is a synthetic antibiotic which is used for the treatment of infections caused by aerobic Gram-positive bacteria. … [A233425] A second member of this class, [tedizolid], was approved by the FDA in 2014 and is considered generally more effective and tolerable than its predecessor.

  9. Drug

    Ipratropium

    go.drugbank.com/drugs/DB00332
    ApprovedInvestigational

    [A176957] Ipratropium as a therapeutic agent was developed by Boehringer Ingelheim and its first monotherapy product was FDA approved in 1986, while the combination product of ipratropium and [albuterol

  10. Drug

    Erenumab

    go.drugbank.com/drugs/DB14039
    ApprovedInvestigational

    In particular, erenumab-aooe is a human immunoglobulin G2 monoclonal antibody that has high affinity binding to the CGRP receptor [FDA Label]. … Aimovig, as released and marketed by Novartis and Amgen, is in fact a novel therapeutic approach as the first and only FDA approved treatment specifically developed to prevent migraine by blocking the